Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment.

ABSTRACT:

Background and aim

Several reports have demonstrated that skeletal muscle mass influences mortality in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment; however, there is still controversy with regard to whether skeletal muscle and adipose tissue are associated with the prognosis in HCC patients. We examined the relationship between body composition and prognosis in HCC patients.

Methods

We retrospectively analyzed 82 patients with unresectable HCC receiving sorafenib treatment. The skeletal muscle area and adipose tissue area were measured by computed tomography. Patients with low skeletal muscle index (male ≤36.2 cm²/m², female ≤29.6 cm²/m²) and high visceral to subcutaneous adipose tissue area ratio (VS

SUBMITTER: Sawada K 

PROVIDER: S-EPMC6684515 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature